9H469H46 の概要
| エントリーDOI | 10.2210/pdb9h46/pdb |
| 分子名称 | Epidermal growth factor receptor, 5-ethyl-2-[(2-methoxyphenyl)amino]-8-phenyl-pyrido[2,3-d]pyrimidin-7-one (3 entities in total) |
| 機能のキーワード | kinase, egfr, inhibitor, transferase |
| 由来する生物種 | Homo sapiens (human) |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 37807.75 |
| 構造登録者 | |
| 主引用文献 | Stewart, H.L.,Bordoni, C.,Jennings, C.E.,Al-Khawaldeh, I.,Martin, M.P.,Noble, R.A.,Phillips, N.,Pintar, S.,Prendergast, L.,Thomas, H.D.,Wang, L.Z.,Watt, J.E.,Wittner, A.,Bronowska, A.K.,Cano, C.,Noble, M.E.M.,Wedge, S.R.,Waring, M.J. Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies. J.Med.Chem., 69:533-552, 2026 Cited by PubMed Abstract: Inhibitors of epidermal growth factor receptor (EGFR) kinase activity are clinically effective treatments for lung cancers driven by activating mutations in EGFR. Resistance to inhibitors develops over time, frequently through further mutations in the kinase domain. On-target resistance to third-generation inhibitor osimertinib, commonly develops through C797S mutation that prevents covalent binding. There is an urgent need for new treatments for osimertinib-resistant EGFR mutants that retain the advantages of the covalent mechanism. Compounds were designed and synthesized to covalently inhibit EGFR through C775, a further cysteine residue we identified in the orthosteric site. Optimisation of the alkynylpyridopyrimidinone scaffold we discovered led to potent compounds that demonstrate inhibition of EGFR phosphorylation and tumor growth in all EGFR mutant cell lines. The covalent C775 mode-of-action was comprehensively established. This work demonstrates that covalent targeting of C775 is a viable mechanism for the treatment of pan-EGFR mutated cancers, particularly those resistant to current therapies. PubMed: 41432179DOI: 10.1021/acs.jmedchem.5c02924 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (3.163 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
をダウンロード
